February 14, 2025

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics Inc. (The Company) announces that the non-operating income, non-operating expenses, and extraordinary losses were recorded in the first nine months of the fiscal year 2025/03. The details are as follows:

1. Non-operating income

   The Company has recorded foreign exchange income of 7,643 thousand yen, outsourcing service income of 1,772 thousand yen, and interest income of 707 thousand yen respectively as non-operating income.

2. Non-operating expenses

   The Company has recorded taxes and dues associated with capital increase through exercise of share acquisition rights of 3,271 thousand yen and share issuance costs of 961 thousand yen as non-operating expenses.

3. Extraordinary losses

   The Company has recorded impairment losses of 68,383 thousand yen for its non-current assets in accordance with the Accounting Standard for Impairment of Fixed Assets as extraordinary losses.

4. Impact on financial results

   The above items have been fully reflected in the “Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025” announced today.

END